Back to today’s briefing

Story perspectives

Novo Nordisk Sues KBP for $830M; FDA Approves New Cancer Drug

2/22/2025

34 6

Summary

Novo Nordisk Sues

Novo Nordisk is taking KBP Biosciences to court, seeking a staggering $830 million over accusations of deceit tied to a hypertension drug. In a significant move, AstraZeneca has snapped up FibroGen's China unit for $160 million. Meanwhile, hope shines for patients as Ono Pharmaceutical's vimseltinib (Romvimza) gains FDA approval, providing a safer treatment for tenosynovial giant cell tumors.

Summary

FDA Approves Ctexli

In a groundbreaking move, the FDA has greenlit Ctexli (chenodiol) from Mirum Pharmaceuticals, marking the first-ever treatment for cerebrotendinous xanthomatosis (CTX), a rare lipid storage disorder. This innovative drug effectively lowers harmful cholesterol metabolites, providing hope to patients who have long faced a lack of effective options. Side effects may include diarrhea and headaches.

1 of 2

Novo Nordisk Sues

Novo Nordisk is taking KBP Biosciences to court, seeking a staggering $830 million over accusations of deceit tied to a hypertension drug. In a significant move, AstraZeneca has snapped up FibroGen's China unit for $160 million. Meanwhile, hope shines for patients as Ono Pharmaceutical's vimseltinib (Romvimza) gains FDA approval, providing a safer treatment for tenosynovial giant cell tumors.

1 / 2